The short answer
Growth hormone acts on the liver, which produces IGF-1, and circulating IGF-1 feeds back to suppress further growth hormone release. Many effects attributed to growth hormone are mediated by IGF-1 rather than by growth hormone acting directly.
Key facts
- Sequence
- Pituitary GH → liver → IGF-1
- Feedback
- IGF-1 suppresses GH release
- In Laron syndrome
- GH high, IGF-1 very low
- Why
- Feedback arm is absent
- Liver as endocrine organ
- Rhyu 2021 (PMID 34904032)
- Related on this site
- GHRH analogues and secretagogues
The sequence of events
The pituitary releases growth hormone in pulses. Growth hormone acts on hepatocytes, which produce IGF-1 and release it into circulation. IGF-1 then acts on peripheral tissues and also returns to the hypothalamus and pituitary, where it suppresses further growth hormone release. It is a classical endocrine loop with the liver as the middle step.
Why the intermediary matters
Many effects historically attributed to growth hormone are produced by IGF-1 rather than by growth hormone acting on the tissue directly. Growth hormone is in that sense partly an instruction to the liver, and the liver's product does much of the work. For that reason the two cannot be treated as interchangeable.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
What Laron syndrome does to the loop
It breaks the middle step. Growth hormone is produced and released normally but cannot be received, so IGF-1 production fails. Because IGF-1 is the feedback signal, its absence removes the brake and growth hormone rises further. The result is the characteristic combination of high growth hormone with very low IGF-1, a pattern that identifies the condition.
The liver as an endocrine organ
Rhyu and colleagues reviewed newly discovered endocrine functions of the liver in the World Journal of Hepatology in 2021. IGF-1 production is the long-established example, and it is a useful corrective to thinking of the liver purely as a metabolic and detoxifying organ. It is also a hormone-secreting tissue responding to a pituitary signal.
Why this connects to other compounds in this catalogue
Growth hormone releasing hormone analogues and growth hormone secretagogues act at the top of this loop, stimulating pituitary release. IGF-1 and its analogues act at the bottom, supplying the downstream mediator directly. They engage the same axis from opposite ends, and the feedback arm means an intervention at either end affects the other.
Why direct supply bypasses the regulation
Stimulating the pituitary produces IGF-1 through a loop that includes its own suppression: more IGF-1 means less growth hormone means less IGF-1. Supplying IGF-1 directly enters below that control point, so the feedback that would normally limit it is not engaged in the same way. That is a structural difference between acting at the top of an axis and acting at the bottom.
Quick reference
| Normal | Laron syndrome | |
|---|---|---|
| Growth hormone | Pulsatile, regulated | High |
| GH receptor | Functional | Defective |
| IGF-1 | Produced by liver | Very low |
| Feedback on GH | Present | Absent |
Frequently asked questions
Does growth hormone act directly on tissues?
Partly, but many effects attributed to it are mediated by IGF-1, which the liver produces in response to it.
Why is growth hormone high in Laron syndrome?
IGF-1 is the feedback signal that suppresses it. Without IGF-1 production, that brake is absent.
How does this relate to GHRH analogues?
They act at the top of the loop by stimulating pituitary release; IGF-1 analogues act at the bottom by supplying the mediator directly.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedRhyu J, Yu R, Newly discovered endocrine functions of the liver. World J Hepatol 2021 (PMID 34904032)pubmed.ncbi.nlm.nih.gov
- PubMedLaron Z, Laron syndrome: a historical perspective. Rev Endocr Metab Disord 2021 (PMID 32964395)pubmed.ncbi.nlm.nih.gov
- PubMedBereket A et al., Alterations in the growth hormone-insulin-like growth factor axis. Horm Metab Res 1999 (PMID 10226799)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- Two Receptors Close Enough to Form HybridsThe IGF-1 and insulin receptors share structure and can assemble into hybrids containing subunits of both. Selectivity is therefore never absolute.
- Eighty-Three Residues, and What That ChangesRegulators treat 40 amino acids as the boundary between peptide and protein. At 83 residues, IGF-1 LR3 is well past it - with consequences.
- What Is IGF-1 LR3? Why It Is a Protein, Not a PeptideAn 83-residue engineered IGF-1 analogue built to evade binding proteins. Why it is a protein rather than a peptide, and what that changes.
- IGF Binding Proteins and the Free FractionMost circulating IGF-1 is sequestered in a ternary complex with IGFBP-3 and the acid-labile subunit. That system is what LR3 was designed to evade.
- IGF-1 LR3 Structure: Three Disulfides and Why They Matter83 residues folded by three disulfide bonds. Milner 1995 showed B-domain mutations affect oxidative folding - and position 3 is in the B-domain.